Related Experiment Video

Updated: Jun 19, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

WIP1 phosphatase at the crossroads of cancer and aging

Xavier Le Guezennec1, Dmitry V Bulavin

  • 1Institute of Molecular and Cell Biology, Cell Cycle Control and Tumorigenesis Group, 61 Biopolis Drive, Proteos, Singapore.

Trends in Biochemical Sciences
|November 3, 2009
PubMed

Insights

The phosphatase WIP1 (also known as PPM1D) promotes cancer by inhibiting tumor suppressors. It also impacts aging, making it a potential therapeutic target for both cancer and aging.

Area of Science:

  • Oncology
  • Molecular Biology
  • Aging Research

Background:

  • The serine/threonine phosphatase WIP1 (PPM1D) exhibits oncogenic properties by inhibiting key tumor suppressor pathways like ATM, CHK2, p38MAPK, and p53.
  • Aberrant amplification of the PPM1D gene is observed in human cancers, and its absence confers tumor resistance in mice.

Purpose of the Study:

  • To investigate the multifaceted roles of WIP1 in cancer and aging.
  • To evaluate WIP1 as a potential therapeutic target for age-related diseases and cancer.

Main Methods:

  • Review of genetic studies and downstream target identification for WIP1.
  • Analysis of recent evidence on WIP1's role in regulating cell proliferation in self-renewing tissues.

Main Results:

  • WIP1 inhibits multiple tumor suppressor pathways, contributing to tumorigenesis.
  • WIP1 plays a role in the age-related decline of proliferation in specific cell types, such as pancreatic beta-cells.

Conclusions:

  • WIP1's dual role in cancer and aging presents it as a significant therapeutic target.
  • Targeting WIP1 may offer novel strategies for combating cancer and age-related decline.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...